How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →

NiKang Therapeutics® Completes Dosing of the First Cohort in a Phase 1 Study of NKT5097, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2/4 Dual Degrader

calendar_today September 8, 2025 person Elizabeth Aspinall domain nikang-therapeutics

See the press release on Business Wire